[Berofor alpha 2 (r-HUIFN-alpha 2 arg) and acyclovir in the treatment of dendritic keratitis].
In a double-masked clinical trial a total of 24 patients have so far been treated with recombinant human alpha 2-interferon in combination with Acyclovir (ACV), and 21 patients with a placebo-Acyclovir combination. Both partial and complete healing times were statistically significantly shortened in the r-Hu IFN-alpha 2-AVC group, by 35 and 32 percent respectively. No difference could be demonstrated between the combination of r-Hu IFN-alpha 2 arg and ACV and that of BCL IFN and ACV as far as the therapeutic effect was concerned. R-Hu IFN-alpha 2 drops in combination with Acyclovir ointment were excellently tolerated.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I; D016898:Interferon-alpha; D007371:Interferon-gamma / Q000008:administration & dosage*; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D009883:Ophthalmic Solutions; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage
D007370:Interferon Type I; D016898:Interferon-alpha; D009824:Ointments; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D007371:Interferon-gamma; C554129:interferon alfa-2c; D000212:Acyclovir
Berofor Alpha 2 (r-Hu IFN-alpha 2 arg) und Aciclovir in der Behandlung der Herpes-Keratitis-dendritica.